Magáli Mocellin

Magáli Mocellin

Auto-generated profile, based on publicly available information

Magáli Mocellin

Pontifícia Universidade Católica do Rio Grande do Sul (PUCRS), Escola de Medicina, Núcleo de Pediatria, Centro Infantil, Porto Alegre, RS, Brazil

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2020 in Jornal Brasileiro de Pneumologia
Verified
Journal Article
Open access
PDF file
FLFernanda Luisi Luisi
Fernanda Luisi Luisi
CRClarissa Aires Roza
Clarissa Aires Roza
VSVictória D'Azevedo Silveira
Victória D'Azevedo Silveira
CMCamila Correia Machado
Camila Correia Machado
KRKatiana Murieli da Rosa
Katiana Murieli da Rosa
LPLeonardo Araújo Pinto
Leonardo Araújo Pinto
Objective: A significant proportion of the infants developed recurrent wheezing after an acute bronchiolitis (AB) event. Recent studies have demonstrated protection for recurrent wheeze and lower respiratory morbidity in infants treated with azithromycin during an acute respiratory wheezing. The aim of the present study was to test the hypothesis that administration of azithromycin during an AB event reduces subsequent wheezing and hospital re-admissions. Methods: This is a secondary analysis of a randomized, double-blinded, placebo-controlled trial, including unpublished data of wheezing and hospitalizations during the initial 6 months following admission for acute viral bronchiolitis. The study was performed in a tertiary University hospital. Infants (<12 months of age) hospitalized with AB were randomized to receive either azithromycin or placebo, administered orally, for 7 days. Families were contacted by telephone at 3 and 6 months after the initial acute event and answered to a standardized questionnaire in order to identify recurrent wheezing and hospital readmissions. Results: One hundred and four patients were included (Azithromycin group, n=50; placebo group, n=54). Considering the total of patients contacted 3 months after hospitalization (n=70), the recurrence rate of wheezing in the azithromycin group was significantly lower than in the placebo group (RR = 0.48; CI = 0.24-0.98; p = 0.038). Conclusion: Azithromycin significantly reduces the risk of subsequent wheezing between 0 and 3 months after hospital admission due to acute bronchiolitis irrespective of the presence of respiratory syncytial virus.

28 November 2016 in Epidemiology and Infection
Verified
Journal Article
Open access
PDF file
LPL. A. Pinto
L. A. Pinto
LLL. A. DE Azeredo Leitão
L. A. DE Azeredo Leitão
MMM. Mocellin
M. Mocellin
Patricio L AcostaPatricio L Acosta
Patricio L Acosta
MCMauricio Tomas Caballero
Mauricio Tomas Caballero
ASAna Paula Duarte De Souza
Ana Paula Duarte De Souza
Clinical manifestations of acute bronchiolitis (AB) vary from minimal disease to severe respiratory failure. The response to respiratory viral infections is possibly influenced by genetic polymorphisms linked to the regulation of the inflammatory response. In the present study, we investigated whether interleukin-8 (IL-8) and interleukin-17 (IL-17) genetic variants are associated with the severity of AB. A group of Brazilian infants hospitalized with AB and a control group (infants with no or mild AB, without hospitalization) were genotyped for four IL-8/IL-17 variations. For replication, we studied an Argentinean population sample of infants with mild and severe AB. IL-8 polymorphism (rs 2227543) and IL-17 (rs2275913) variants showed significant associations with the severity of AB. The effect of the IL-8 variation could be replicated in the Argentinean sample. This finding suggests that IL-8 variations may influence the severity of AB in young infants. Further genetic association studies in low- or middle-income populations are necessary with the aim of expanding knowledge in this area.

19 February 2020 in Einstein (São Paulo)
Verified
Journal Article
Open access
PDF file
FSFátima Cleonice de Souza
Fátima Cleonice de Souza
MMMagáli Mocellin
Magáli Mocellin
RORenata Ongaratto
Renata Ongaratto
LLLidiane Alves de Azeredo Leitão
Lidiane Alves de Azeredo Leitão
FFFrederico Friedrich
Frederico Friedrich
LPLeonardo Araújo Pinto
Leonardo Araújo Pinto
To compare the frequency of respiratory tract infections in children treated with OM-85 BV and placebo during the 3-month therapy period, and observation for a further 3 months after treatment. A randomized, double-blind, placebo-controlled trial was conducted with 54 children (6 months to 5 years old) with no past history of recurrent respiratory infections attending daycare center. Family members were instructed to administer one capsule per day for 10 consecutive days, for 3 months of OM-85 BV or placebo. Telephone interviews were conducted every 30 days. There was no significant difference in the number of respiratory infections between the groups. The mean number of respiratory tract infection in the OM-85 BV Group in the first 3 months was 0.92±0.87, and in the Placebo Group was 0.74±1.02, and at 6 months it was 1.62±1.47 and 1.03±1.34, respectively. OM-85 BV was not effective in the primary prevention of respiratory tract infections. Although most authors recommend the use of this immunostimulant in children with a history of recurrent respiratory infections, more studies are needed to define its usefulness in the primary prevention of respiratory infections in healthy children exposed to few risk factors.

2 January 2021 in Jornal de Pediatria
Verified
Journal Article
Open access
MMMagáli Mocellin
Magáli Mocellin
LLLidiane Alves de Azeredo Leitão
Lidiane Alves de Azeredo Leitão
PAPatrícia Dias de Araújo
Patrícia Dias de Araújo
MJMarcus Herbert Jones
Marcus Herbert Jones
RSRenato Tetelbom Stein
Renato Tetelbom Stein
LPLeonardo Araújo Pinto
Leonardo Araújo Pinto
The aim of this study was to evaluate the association between possible functional interleukin-10 (IL-10) polymorphisms, IL-10 expression and regulatory T cells (Tregs) frequency, and/or asthma severity in a sample of children and adolescents. This is a nested case-control genetic association study. The study sample consisted of children and adolescents aged 8-14 from public schools. Four polymorphisms of the IL-10 gene (rs1518111, rs3024490, rs3024496, rs3024491) were genotyped in asthmatic subjects and controls using real-time PCR. Tregs cells and IL-10 were analyzed in peripheral blood mononuclear cells by flow cytometry. The severity of asthma was defined according to the Global Initiative for Asthma (GINA) guideline. One hundred twenty-three asthmatic subjects and fifty-eight controls participated in the study. The single nucleotide polymorphism (SNP) rs3024491 (T allele) showed association with asthma severity, presenting a higher frequency in patients in the moderate asthma group. The T allele of variant rs3024491 also showed an association with reduced IL-10 levels (p=0.01) and with increased Tregs frequency (p=0.01). The other variants did not present consistent associations. Our results suggest that moderate asthma is associated with a higher frequency of the T allele in the SNP rs3024491. In addition, the variant rs3024491 (TT) was associated with a reduction in IL-10 production and an increased percentage of Tregs cells, suggesting possible mechanisms that influence asthma severity.